Nyrada (ASX:NYR) - CEO, James Bonnar
CEO, James Bonnar
Source: Perth Now
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Nyrada (NYR) announces its first-in-human study for cholesterol lowering is expected to begin during the first half of 2023
  • NYR pinpointed the main driver of the delay to employees being unable access laboratory sites while the extended lockdowns in Shanghai remained in place
  • Despite the setback, the company’s preclinical safety and toxicology studies are still expected to begin in the third quarter of 2022
  • Meanwhile, Nyrada has been granted a European patent for its novel compounds inhibiting PCSK9, providing protection for the intellectual property until 16 March, 2038
  • Company shares drop 6.67 per cent, trading at 14 cents at 1:20 pm AEST

Nyrada (NYR) has announced its first-in-human study for cholesterol lowering is expected to begin during the first half of 2023.

As a result of scale-up drug manufacturing delays caused by COVID-related lockdowns in Shanghai, the phase one study is now expected to commence next year.

Nyrada pinpointed the main driver of this delay to the inability of employees of the contract manufacturing organisation engaged by Nyrada to access laboratory sites while the extended lockdown remained in place.

Despite the setback, the company’s preclinical safety and toxicology studies are still expected to begin in the third quarter of 2022.

The primary aim of the study is to evaluate Nyrada’s drug candidate for safety and tolerability, while also assessing blood cholesterol levels in cohorts treated for 14 days.

Nyrada CEO, James Bonnar said he was pleased the preclinical studies remain on track to start in Q3 CY2022.

“Nyrada’s clinical candidate oral PCSK9 inhibitor creates the potential for a next generation alternative to expensive and inconvenient PCSK9 injectable drugs and is attracting industry interest,” he said.

Meanwhile, Nyrada has been granted a European patent for its novel compounds inhibiting PCSK9, providing protection for the intellectual property until 16 March, 2038.

Nyrada now holds patent protection for the compounds in both the US and European Union.

Company shares dropped 6.67 per cent, trading at 14 cents at 1:20 pm AEST.

NYR by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…